The management of ocular surface squamous neoplasia (OSSN)
The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensu...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/169558 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-169558 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1695582023-07-30T15:37:57Z The management of ocular surface squamous neoplasia (OSSN) Yeoh, Clarice H. Y. Lee, Jerome J. R. Lim, Blanche X. H. Sundar, Gangadhara Mehta, Jodhbir S. Chan, Anita S. Y. Lim, Dawn K. A. Watson, Stephanie L. Honavar, Santosh G. Manotosh, Ray Lim, Chris H. L. Lee Kong Chian School of Medicine (LKCMedicine) Yong Loo Lin School of Medicine, NUS National University Health System Science::Medicine Ocular Surface Squamous Neoplasia Topical Chemotherapy The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensus regarding the best way to manage OSSN with no existing guidelines to date. This paper seeks to evaluate evidence surrounding available treatment modalities and proposes an approach to management. The approach will guide ophthalmologists in selecting the most appropriate treatment regime based on patient and disease factors to minimize treatment related morbidity and improve OSSN control. Further work can be done to validate this algorithm and to develop formal guidelines to direct the management of OSSN. Published version Publication fees associated with this article have been funded through the ExxonmobileNUS grant awarded to Chris Lim. 2023-07-24T06:49:21Z 2023-07-24T06:49:21Z 2023 Journal Article Yeoh, C. H. Y., Lee, J. J. R., Lim, B. X. H., Sundar, G., Mehta, J. S., Chan, A. S. Y., Lim, D. K. A., Watson, S. L., Honavar, S. G., Manotosh, R. & Lim, C. H. L. (2023). The management of ocular surface squamous neoplasia (OSSN). International Journal of Molecular Sciences, 24(1), 713-. https://dx.doi.org/10.3390/ijms24010713 1661-6596 https://hdl.handle.net/10356/169558 10.3390/ijms24010713 36614155 2-s2.0-85145979362 1 24 713 en International Journal of Molecular Sciences © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Science::Medicine Ocular Surface Squamous Neoplasia Topical Chemotherapy |
spellingShingle |
Science::Medicine Ocular Surface Squamous Neoplasia Topical Chemotherapy Yeoh, Clarice H. Y. Lee, Jerome J. R. Lim, Blanche X. H. Sundar, Gangadhara Mehta, Jodhbir S. Chan, Anita S. Y. Lim, Dawn K. A. Watson, Stephanie L. Honavar, Santosh G. Manotosh, Ray Lim, Chris H. L. The management of ocular surface squamous neoplasia (OSSN) |
description |
The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensus regarding the best way to manage OSSN with no existing guidelines to date. This paper seeks to evaluate evidence surrounding available treatment modalities and proposes an approach to management. The approach will guide ophthalmologists in selecting the most appropriate treatment regime based on patient and disease factors to minimize treatment related morbidity and improve OSSN control. Further work can be done to validate this algorithm and to develop formal guidelines to direct the management of OSSN. |
author2 |
Lee Kong Chian School of Medicine (LKCMedicine) |
author_facet |
Lee Kong Chian School of Medicine (LKCMedicine) Yeoh, Clarice H. Y. Lee, Jerome J. R. Lim, Blanche X. H. Sundar, Gangadhara Mehta, Jodhbir S. Chan, Anita S. Y. Lim, Dawn K. A. Watson, Stephanie L. Honavar, Santosh G. Manotosh, Ray Lim, Chris H. L. |
format |
Article |
author |
Yeoh, Clarice H. Y. Lee, Jerome J. R. Lim, Blanche X. H. Sundar, Gangadhara Mehta, Jodhbir S. Chan, Anita S. Y. Lim, Dawn K. A. Watson, Stephanie L. Honavar, Santosh G. Manotosh, Ray Lim, Chris H. L. |
author_sort |
Yeoh, Clarice H. Y. |
title |
The management of ocular surface squamous neoplasia (OSSN) |
title_short |
The management of ocular surface squamous neoplasia (OSSN) |
title_full |
The management of ocular surface squamous neoplasia (OSSN) |
title_fullStr |
The management of ocular surface squamous neoplasia (OSSN) |
title_full_unstemmed |
The management of ocular surface squamous neoplasia (OSSN) |
title_sort |
management of ocular surface squamous neoplasia (ossn) |
publishDate |
2023 |
url |
https://hdl.handle.net/10356/169558 |
_version_ |
1773551326350802944 |